NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a commercial service agreement with the Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata (IDI) research Hospital in Rome to provide its SelectMDx prostate cancer test as a service.
SelectMDx is a urine-based, noninvasive molecular diagnostic test that assesses a man's risk for prostate cancer. Under the terms of the agreement, the IDI Laboratory of Clinical Molecular Diagnostics will purchase SelectMDx CE-marked IVD kits from MDxHealth and will perform the test initially at the MDxHealth central lab in the Netherlands, and then locally.
MDxHealth CEO Jan Groen said in a statement that "IDI's broad hospital network will significantly contribute to the successful market penetration of SelectMDx in Italy."
In its recent 2017 financial report, MDxHealth noted that test volumes for SelectMDx accounted for 35 percent of total product sales volumes during the year. Global test volume for SelectMDx grew to 11,700 in 2017 from 4,000 in 2016, and test volume in Europe rose more than 300 percent to more than 3,100 patients tested compared to 800 in 2016.
In January, the company announced a partnership with UgenTec to develop artificially intelligent software to support interpretation of molecular test results for both its ConfirmMDx and SelectMDx tests.
The firm also signed a distribution deal for SelectMDx in Spain last November.